Recro Pharma (NASDAQ: REPH) is a specialty pharmaceutical company that engages in developing non-opioid products for the treatment of acute pain. Its lead product candidate includes injectable meloxicam, a development stage product for the treatment of acute post-operative pain. The company also is developing Dex-IN, an intranasal formulation of dexmedetomidine for the treatment of acute peri-procedural pain, Dex-SL, a product for the
treatment of chronic pain and Fadolmidine, an alpha-2 agonist product candidate administered by injection into the intrathecal space for pain associated with surgery or chronic pain associated with nerve damage to local tissues (neuropathies). For more information, visit the company’s website at www.recropharma.com.
About NetworkNewsWire
NetworkNewsWire (NNW) provides news aggregation and syndication, enhanced press release services and a full array of social communication solutions. As a multifaceted financial news and distribution company with an extensive team of journalists and writers, NNW is uniquely positioned to best serve private and public companies who need to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
For more information, visit https://www.networknewswire.com
Please see full disclaimers on the NetworkNewsWire website: http://nnw.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.networknewswire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
